Our data analysis in Figure 6 shows that 34% of the melanoma patients presented alteration on the TRX1 gene, while 7% showed alterations on TRX2, 8% on TR1 and TXNIP, 13% on TR2, and 10% on TR3. This evidence concerns the gene TXNIP and melanoma.